Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Other Accumulated Expenses (2021 - 2025)

Relay Therapeutics (RLAY) has disclosed Other Accumulated Expenses for 5 consecutive years, with $463000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 76.73% to $463000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $463000.0 through Dec 2025, down 76.73% year-over-year, with the annual reading at $463000.0 for FY2025, 76.73% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $463000.0 at Relay Therapeutics, down from $1.1 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $26.9 million in Q3 2022, with the low at $396000.0 in Q4 2021.
  • Average Other Accumulated Expenses over 5 years is $8.7 million, with a median of $1.7 million recorded in 2024.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 6504.04% in 2022, then tumbled 96.96% in 2024.
  • Over 5 years, Other Accumulated Expenses stood at $396000.0 in 2021, then surged by 6504.04% to $26.2 million in 2022, then plummeted by 95.4% to $1.2 million in 2023, then skyrocketed by 65.28% to $2.0 million in 2024, then tumbled by 76.73% to $463000.0 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $463000.0, $1.1 million, and $609000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.